Drugs, Wound Healing and Cutaneous Ulcers


Systemic Lupus Erythematosus Skin Necrosis Pyoderma Gangrenosum Cutaneous Ulcer Cutaneous Necrosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bork K: Ulcers and necroses; atrophies. In: Cutaneous Side Effects of Drugs, 1st edn. Philadelphia: WB Saunders. 1988; pp 360–369Google Scholar
  2. 2.
    Kohler LD, Schwedler S, Worret WI: Embolia cutis medicamentosa. Int J Dermatol 1997; 36:197CrossRefPubMedGoogle Scholar
  3. 3.
    Kunzi T, Ramstein C, Pirovino M: Circumscribed skin necrosis following intramuscular injection (embolia cutis medicamentosa). Schweiz Rundsch Med Prax 1995; 84:640–643PubMedGoogle Scholar
  4. 4.
    Muller-Vahl H: Aseptic tissue necrosis: a severe complication after intramuscular injections. Dtsch Med Wochenschr 1984; 109:786–792PubMedGoogle Scholar
  5. 5.
    Gammel JA: Arterial embolism, an unusual complication following the intramuscular administration of bismuth. JAMA 1927; 88:998Google Scholar
  6. 6.
    Fiscina S: Injections followed by a sterile abscess. Mil Med 1986; 151:452PubMedGoogle Scholar
  7. 7.
    Smith AL, Khan F, De Mello W: Sterile abscess formation following plague vaccination. J R Army Med Corps 1997; 143:116–117PubMedGoogle Scholar
  8. 8.
    Cosman A, Feliciano WC, Wolff M: Pentazocine ulcers. Plast Reconst Surg 1977; 59:255–259PubMedGoogle Scholar
  9. 9.
    Krainick U, Kantarjian H, Broussard S, et al: Local cutaneous necrotizing lesions associated with interferon injections. J Interferon Cytokine Res 1998; 18:823–827PubMedGoogle Scholar
  10. 10.
    Webster GF, Knobler RL, Lublin FD, et at: Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon P injections in patients with multiple sclerosis. J Am Acad Dermatol 1996;34:365–367PubMedGoogle Scholar
  11. 11.
    Weinberg JM: Cutaneous necrosis associated with recombinant interferon injection. J Am Acad Dermatol 1998; 39:807–808PubMedGoogle Scholar
  12. 12.
    Oeda E, Shinohara K: Cutaneous necrosis caused by injection of a-interferon in a patient with chronic myelogenous leukemia. Am J Hematol 1993; 44:213–214Google Scholar
  13. 13.
    Gaines AR, Varricchio F: Interferon ß-1b injection site reactions and necroses. Mult Scler 1998; 4:70–73CrossRefPubMedGoogle Scholar
  14. 14.
    Weinberg JM, Wolfe JT, Sood S, et al: Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-lb and review of the literature. Acta Derm Venereol (Stockh) 1997; 77:146–148PubMedGoogle Scholar
  15. 15.
    Hinterberger JW, Kintzi HE: Phentolamine reversal of epinephrine-induced digital vasospasm. How to save an ischemic finger. Arch Fam Med 1994; 3:193–195CrossRefPubMedGoogle Scholar
  16. 16.
    Maguire WM, Reisdorff EJ, Smith D, Weigenstein JG: Epinephrine-induced vasospasm reversed by phentolamine digital block. Am J Emerg Med 1990;8:46–47CrossRefPubMedGoogle Scholar
  17. 17.
    Bork K: Necrosis and ulcers. In: Cutaneous Side Effects of Drugs. 1st edn. Philadelphia: W.B Saunders. 1988; pp 220–230Google Scholar
  18. 18.
    Sylaidis P, Logan A: Digital blocks with adrenaline. An old dogma refuted. J Hand Surg [Br] 1998; 23:17–19Google Scholar
  19. 19.
    Rae V, Pardo RJ, Blackwelder PL, et al: Leg ulcers following subcutaneous injection of a liquid silicone preparation. Arch Dermatol 1989; 125:670–673CrossRefPubMedGoogle Scholar
  20. 20.
    Mastruserio DN, Pesqueira MJ, Cobb MW: Severe granulomatous reaction and facial ulceration occurring after sub cutaneous silicone injection. J Am Acad Dermatol 1996; 34:849–852CrossRefPubMedGoogle Scholar
  21. 21.
    Bihari I, Magyar E: Reasons for ulceration after injection treatment of telangiectasia. Dermatol Surg 2001; 27:133–136CrossRefPubMedGoogle Scholar
  22. 22.
    Borgstrom E: Penile ulcer as complication in self-induced papaverine erections. Urology 1988; 32: 416–417CrossRefPubMedGoogle Scholar
  23. 23.
    Brown AS, Hoelzer DJ, Piercy SA: Skin necrosis from extravasation of intravenous fluids in children. Plast Reconstr Surg 1979; 64:145–150PubMedGoogle Scholar
  24. 24.
    Riyami A: Complications of intravenous infusions. J Ir Med Assoc 1968; 61:23–25PubMedGoogle Scholar
  25. 25.
    Disa JJ, Chang RR, Mucci SJ, et at: Prevention of Adriamycin induced full-thickness skin loss using hyaluronidase infiltration. Plast Reconstr Surg 1998; 101:370–374PubMedGoogle Scholar
  26. 26.
    Barden GA: Venous extravasation of doxorubicin HCI with secondary skin ulceration. South Med J 1980; 73:1543–1544PubMedGoogle Scholar
  27. 27.
    Mehta P, Najar N: Skin ulceration due to faulty adriamycin administration. Clin Pediatr (Phila) 1978;17:663–664Google Scholar
  28. 28.
    Luedke DW, Kennedy PS, Rietschel RL: Histopathogenesis of skin and subcutaneous injury induced by Adriamycin. Plast Reconstr Surg 1979; 63:463–465PubMedGoogle Scholar
  29. 29.
    Bowers DG Jr, Lynch JB: Adriamycin extravasation. Plast Reconstr Surg 1978; 61:86–92PubMedGoogle Scholar
  30. 30.
    Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Saf 1995; 12:245–255PubMedGoogle Scholar
  31. 31.
    Boman NL, Tron VA, Bally MB, et al: Vincristine induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol 1996; 37:351–355PubMedGoogle Scholar
  32. 32.
    Blair WF, Kilpatrick WC Jr, Saiki JH, Alter EJ: Extravasation of chemotherapeutic agents. Clin Orthop 1980; 151:228–230PubMedGoogle Scholar
  33. 33.
    Bairey O, Bishara J, Stahl B, et al: Severe tissue necrosis after cisplatin extravasation at low concentration: possible “immediate recall phenomenon”. J Natl Cancer Inst 1997; 89:1233–1234CrossRefPubMedGoogle Scholar
  34. 34.
    Elam EA, Dorr RT, Lagel KE, Pond GD: Cutaneous ulceration due to contrast extravasation. Experimental assessment of injury and potential antidotes. Invest Radiol 1991; 26:13–16PubMedGoogle Scholar
  35. 35.
    Heckler FR: Current thoughts on extravasation injuries. Clin Plast Surg 1989; 16:557–563PubMedGoogle Scholar
  36. 36.
    Rudolph R, Stein RS, Pattillo RA: Skin ulcers due to Adriamycin. Cancer 1976; 3:1087–1094Google Scholar
  37. 37.
    Sintenie JB, Tuinebreijer WE, Kreis RW, et al: Digital gangrene after accidental intra-arterial injection of phenytoin (epanutin). Eur J Surg 1992; 158:315–316PubMedGoogle Scholar
  38. 38.
    Joist A, Tibesku CO, Neuber M, et al: Gangrene of the fingers caused by accidental intra-arterial injection of diazepazn. Dtsch Med Wochenschr 1999;124:755–758PubMedGoogle Scholar
  39. 39.
    Steib A, Jeanpierre C, Mole JP, et al: Tissue necrosis after accidental perivenous injection of dopamine. Ann Fr Anesth Reanim 1984; 3:328–329CrossRefPubMedGoogle Scholar
  40. 40.
    De Myttenaere S, Heifetz M, Shilansky H, et al: Different treatments used in a case of gangrene due to accidental intra-arterial injection of methylphenidate (rilatine). Anesth Analg (Paris) 1977; 34: 405–410Google Scholar
  41. 41.
    Schanzer H, Gribetz I, Jacobson JH: Accidental intra-arterial injection of penicillin G. A preventable catastrophe. JAMA 1979; 242:1289–1290CrossRefPubMedGoogle Scholar
  42. 42.
    Schanzer H, Jacobson JH: Tissue damage caused by the intramuscular injection of long-acting penicillin. Pediatrics 1985; 75:741–744PubMedGoogle Scholar
  43. 43.
    Wynne JM, Williams GL, Ellman BA: Accidental intra-arterial injection. Arch Dis Child 1978; 53: 396–400PubMedGoogle Scholar
  44. 44.
    Yasin M, Vishne TH, Hendel D: Local necrosis of finger following stab with needle used to pump terbutaline sulfate (bricalin). Harefuah 2001; 140: 398–399PubMedGoogle Scholar
  45. 45.
    Bertoncini RL, Silveira PG, Ceola L, et at: Vascular complications in intravenous drug addicts. Rev Assoc Med Bras 1992; 38:204–208PubMedGoogle Scholar
  46. 46.
    Abidin MR, Gillinov MA, Topol BM, et al: Injection of illicit drugs into the granulation tissue of chronic ulcers. Ann Plast Surg 1990; 24:268–270PubMedGoogle Scholar
  47. 47.
    Dunne JH, Johnson WC: Necrotizing skin lesions in heroin addicts. Arch Dermatol 1972; 105:544–547CrossRefPubMedGoogle Scholar
  48. 48.
    Fellner MJ, Ledesma GN: Leg ulcers secondary to drug reactions. Clin Dermatol 1990; 8:144–149CrossRefPubMedGoogle Scholar
  49. 49.
    Kirchenbaum SE, Midenberg ML: Pedal and lower extremity complications of substance abuse. J Am Podiatry Assoc 1982; 72:380–387PubMedGoogle Scholar
  50. 50.
    Jackson RM, Tucker SB, Abraham JL, et al: Factitial cutaneous ulcers and nodules: the use of electronprobe microanalysis in diagnosis. J Am Acad Dermatol 1984; 11:1065–1069PubMedGoogle Scholar
  51. 51.
    Gschnait F, Brenner W, Berger E, et al: An unusual case of repeated self-mutilation. Wien Kim Wochenschr 1981; 93:127–131Google Scholar
  52. 52.
    Qaryoute SM: Skin ulceration induced by kerosene injection. Ann Plast Surg 1984; 12:361–363PubMedGoogle Scholar
  53. 53.
    Shapiro PE: Non infectious granulomas. In: Elder D, Elenitas R, Jaworsky C, Johnson B (eds) Lever's Histopathology of the Skin, 8th edn. Philadelphia: Lippincott-Raven. 1997; pp 317–340Google Scholar
  54. 54.
    Ackerman AB: Nodular and diffuse dermatitis. In: Histologic Diagnosis of Inflammatory Skin Diseases: An Algoritmic Method Based on Pattern Analysis. 1st edn. Baltimore Philadelphia: Lea & Febiger. 1978; pp 385–495Google Scholar
  55. 55.
    Brandt O, Abeck D, Breitbart E, et al: Perianal ergotismus gangraenosus. Hautarzt 1997; 48:199–202CrossRefPubMedGoogle Scholar
  56. 56.
    Baptista AP, Mariano A, Machado A: Peranal ulcers caused by ergotamine-containing suppositories. Acta Med Port 1992; 5:39–41PubMedGoogle Scholar
  57. 57.
    Mochida K, Hisa T, Yasunaga C, et al: Skin ulcerations due to povidone-iodine. Contact Dermatitis 1995; 33:61–62PubMedGoogle Scholar
  58. 58.
    Tierney BP, Stadelmann WK: Necrotizing infection of the face secondary to intranasal impaction of “crack” cocaine. Ann Plast Surg 1999; 43:640–643PubMedGoogle Scholar
  59. 59.
    Bork K: Drug-induced Lupus Erythemtosus. In: Bork K: Cutaneous Side Effects of Drugs. 1st edn. Philadelphia: WB Saunders. 1988; pp 181–184Google Scholar
  60. 60.
    Breathnach SM, Hintner H: Patterns of clinical disease. Types of clinical reaction. In: Breathnach SM, Hintner H: Adverse Drug Reactions and the Skin. 1st edn. Oxford: Blackwell Scientific Publications. 1992; pp 41–136Google Scholar
  61. 61.
    Kissin MW, Williamson RC: Hydrallazine-induced SLE-like syndrome presenting as a leg ulcer. Br Med J 1979; 2:1330Google Scholar
  62. 62.
    Bernstein RM, Egerton-Vernon J, Webster J: Hydralazine-induced cutaneous vasculitis. Br Med J 1980; 280:156–157Google Scholar
  63. 63.
    Gibson GE, Su WP, Pittelkow MR: Antiphospholipid syndrome and the skin. J Am Acad Dermatol 1997; 36:970–982PubMedGoogle Scholar
  64. 64.
    Renfro L, Kamino H, Raphael B, et al: Ulcerative lichen planus-like dermatitis associated with hydroxyurea. J Am Acad Dermatol 1991; 24:143–145PubMedGoogle Scholar
  65. 65.
    Burry JN: Ulcerative lichenoid eruption from methyldopa (letter). Arch Dermatol 1976; 112:880CrossRefGoogle Scholar
  66. 66.
    Massa MC, Jason SM, Gradini R, et at: Lichenoid drug eruption secondary to propranolol. Cutis 1991; 48:41–43PubMedGoogle Scholar
  67. 67.
    Srebrnik A, Bar-Nathan EA, Ilie B, et al: Vaginal ulcerations due to lithium carbonate therapy. Cutis 1991; 48:65–66PubMedGoogle Scholar
  68. 68.
    Ross HJ, Moy LA, Kaplan R, et al: Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer 1991; 68:441–443PubMedGoogle Scholar
  69. 69.
    Gangaram HB, Tan LP, Gan AT, et al: Pyoderma gangrenosum following treatment with isotretinoine. Br J Dermatol 1997; 136:636–637PubMedGoogle Scholar
  70. 70.
    Cohen AD, Grossman N, Halevy S: Pyoderma gangrenosum induced by montelukast sodium — confirmation by interferon-γ (IFN-γ) release test. In: 32nd Annual European society for dermatology research (ESDR) meeting. Geneva: September, 2002Google Scholar
  71. 71.
    Cohen AD, Cagnano E, Halevy S: Ibuprofen-induced pyoderma gangrenosum. J Am Acad Dermatol (in press)Google Scholar
  72. 72.
    Srebrnik A, Shachar E, Brenner S: Suspected induction of a pyoderma gangrenosum-like eruption due to sulpiride treatment. Cutis 2001; 67:253–256PubMedGoogle Scholar
  73. 73.
    Soter NA: Cutaneous necrotizing venulitis. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB (eds) In: Fitzpatrick's Dermatology in General Medicine. 5th edn. New York: McGraw-Hill. 1999; pp 2044–2053Google Scholar
  74. 74.
    Lambert WC, Kolber LR, Proper SA: Leukocytoclastic angiitis induced by clindamycin. Cutis 1982;30:615–619PubMedGoogle Scholar
  75. 75.
    Veraguth AJ, Hauselmann HJ, Hunziker T, Gerber NJ: Vasculitic skin lesions caused by nonsteroidal anti-inflammatory agents. Schweiz Med Wochenschr 1992; 122:923–929PubMedGoogle Scholar
  76. 76.
    Houston BD, Crouch ME, Brick JE, et al: Apparent vasculitis associated with propylthiouracil use. Arthritis Rheum 1979; 22:925–928PubMedGoogle Scholar
  77. 77.
    Carmichael AJ, Paul CJ: Vasculitic leg ulcers associated with diltiazem. Br Med J 1988; 297:562Google Scholar
  78. 78.
    Mosovich B, Biton A, Avinoach I: Vasculitis with cutaneous necrosis induced by oral contraceptive. Harefuah 1991; 120:451–453PubMedGoogle Scholar
  79. 79.
    Menni S, Pistritto G, Gianotti R, et al: Ear lobe bilateral necrosis by levamisole-induced occlusive vasculitis in a pediatric patient. Pediatr Dermatol 1997; 14:477–479PubMedGoogle Scholar
  80. 80.
    Schrodt BJ, Kulp-Shorten CL, Callen JP: Necrotizing vasculitis of the skin and uterine cervix associated with minocycline therapy for acne vulgaris. South Med J 1999; 92:502–504PubMedGoogle Scholar
  81. 81.
    Altmeyer P, Welke S, Renger A, et al: Zur pathogenese der sogenannten Cumarin-Nekrose. Aktuel Dermatol 1976; 2:65–68Google Scholar
  82. 82.
    Slutzki S, Bogokowsky H, Gilboa Y, et al: Coumadin induced skin necrosis. Int J Dermatol 1984; 23: 117–119PubMedGoogle Scholar
  83. 83.
    Tanay A, Yust I, Brenner S, et al: Dermal vasculitis due to coumadin hypersensitivity. Dermatologica 1982; 165:178–185PubMedGoogle Scholar
  84. 84.
    Stoebner PE, Gaspard C, Meynadier J, et al: Tongue necrosis provoked by ergotamine tartrate and disclosing a giant cell arteritis. Eur J Dermatol 1999; 9: 652–653PubMedGoogle Scholar
  85. 85.
    Zavaleta EG, Fernandez BB, Grove MK, et al: St. Anthony's fire (ergotamine induced leg ischemia) — a case report and review of the literature. Angiology 2001; 52:349–356PubMedGoogle Scholar
  86. 86.
    Bongard O, Bounameaux H: Severe iatrogenic ergotism: incidence and clinical importance. Vasa 1991; 20:153–156PubMedGoogle Scholar
  87. 87.
    Payne B, Sasse B, Franzen D, et al: Manifold manifestations of ergotism. Schweiz Med Wochenschr 2000; 130:1152–1156PubMedGoogle Scholar
  88. 88.
    DeFranzo AJ, Marasco P, Argenta LC: Warfarin-induced necrosis of the skin. Ann Plast Surg 1995; 34: 203–208PubMedGoogle Scholar
  89. 89.
    Chan YC, Valenti D, Mansfield AO, et al: Warfarin induced skin necrosis. Br J Surg 2000; 87:266–272CrossRefPubMedGoogle Scholar
  90. 90.
    Ad-El DD, Meirovitz A, Weinberg A, et al: Warfarin skin necrosis: local and systemic factors. Br J Plast Surg 2000; 53:624–626CrossRefPubMedGoogle Scholar
  91. 91.
    Cole MS, Minifee PK, Wolma FJ: Coumarin necrosis — a review of the literature. Surgery 1988; 103: 271–277PubMedGoogle Scholar
  92. 92.
    Faraci PA, Deterling RA Jr, Stein AM, et al: Warfarin induced necrosis of the skin. Surg Gynecol Obstet 1978; 146:695–700PubMedGoogle Scholar
  93. 93.
    Makris M, Bardhan G, Preston FE: Warfarin induced skin necrosis associated with activated protein C resistance. Thromb Haemost 1996; 75: 523–524PubMedGoogle Scholar
  94. 94.
    McGehee WG, Klotz TA, Epstein DJ, et al: Coumarin necrosis associated with hereditary protein C deficiency. Ann Int Med 1984; 101:59–60PubMedGoogle Scholar
  95. 95.
    Broekmans AW: Hereditary protein C deficiency. Haemostasis 1985; 15:233–240PubMedGoogle Scholar
  96. 96.
    Comp P, Elrod J, Karzenski S: Warfarin-induced skin necrosis. Semin Thromb Hemost 1990; 16: 293–298PubMedGoogle Scholar
  97. 97.
    Rose VL, Kwaan HC, Williamson K, et al: Protein C antigen deficiency and warfarin necrosis. Am J Clin Pathol 1986; 86:653–655PubMedGoogle Scholar
  98. 98.
    Ng T, Tillyer ML: Warfarin-induced skin necrosis associated with Factor V Leiden and protein S deficiency. Clin Lab Haematol 2001; 23:261–264CrossRefPubMedGoogle Scholar
  99. 99.
    Broekmans AW, Bertina RM, Loeliger EA, et al: Protein C and the development of skin necrosis during anticoagulant therapy (letter). Thromb Haemost 1983; 49:251PubMedGoogle Scholar
  100. 100.
    Breathnach SM, Hintner H: Anticoagulants, fibrinolytic agents and antiplatlet drugs. In: Adverse Drug Reactions and the Skin, 1st edn. Oxford: Bleckwell Scientific Publications. 1992; pp 247–253Google Scholar
  101. 100.
    Gold JA, Watters AK, O'Brien E: Coumadin versus heparin necrosis. J Am Acad Dermatol 1987; 16: 148–150PubMedGoogle Scholar
  102. 102.
    White PW, Sadd JR, Nensel RE: Thrombotic complications of heparin therapy: including six cases of heparin-induced necrosis. Ann Surg 1979; 190:595–608PubMedGoogle Scholar
  103. 103.
    Levine LE, Bernstein JE, Soltani K, et al: Heparin-induced cutaneous necrosis unrelated to injection sites: a sign of potentially lethal complications. Arch Dermatol 1983; 119:400–403CrossRefPubMedGoogle Scholar
  104. 104.
    Santamaria A, Romani J, Souto JC, et al: Skin necrosis at the injection site induced by low-molecular-weight heparin: case report and review. Dermatology 1998; 196:264–265CrossRefPubMedGoogle Scholar
  105. 105.
    Balestra B, Quadri P, Dermarmels-Biasiutti F, et al: Low-molecular-weight heparin-induced thrombo-cytopenia and skin necrosis distant from injection sites. Eur J Haematol 1994; 53:61–63PubMedGoogle Scholar
  106. 106.
    Montserrat I, Lopez D, Zuazu-Jausoro I, et al: Low-molecular-weight subcutaneous heparin-induced skin necrosis. Blood Coag Fibrinol 1990; 1:751–752Google Scholar
  107. 107.
    Drew PJ, Smith MJ, Milling MA: Heparin-induced skin necrosis and low molecular weight heparins. Ann R Coll Surg Engl 1999; 81:266–269PubMedGoogle Scholar
  108. l08.
    Sirieix ME, Debure C, Baudot N, et al: Leg ulcers and hydroxyurea: Forty-one cases. Arch Dermatol 1999; 135:818–820CrossRefPubMedGoogle Scholar
  109. 109.
    Velez A, Garcia-Aranda JM, Moreno JC: Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor? J Eur Acad Dermatol Venereol 1999; 12:243–244CrossRefPubMedGoogle Scholar
  110. 110.
    Best PJ, Daoud MS, Pittelkow MR, et al: Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med 1998; 128:29–32PubMedGoogle Scholar
  111. 111.
    Weinlich G, Fritsch P: Leg ulcers in patients treated with hydroxyurea for myeloproliferative disorders: what is the trigger? Br J Dermatol 1999; 141:171–172CrossRefPubMedGoogle Scholar
  112. 112.
    Ravandi-Kashani F, Cortes J, Cohen P, et al: Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma 1999; 35:109–118PubMedGoogle Scholar
  113. 113.
    Demircay Z, Comert A, Adiguzel C: Leg ulcers and hydroxyurea: report of three cases with essential thrombocythemia. Int J Dermatol 2002; 41:872–874CrossRefPubMedGoogle Scholar
  114. 114.
    Cohen AD, Hallel-Halevy D, Hatskelzon L, et al: Longitudinal melanonychia associated with hydroxyurea therapy in a patient with essential thrombocytosis. J Eur Acad Dermatol Venereol 1999; 13:137–139CrossRefPubMedGoogle Scholar
  115. 115.
    Lawrence CM, Dahl MG: Two patterns of skin ulceration induced by methotrexate in patients with psoriasis. J Am Acad Dermatol 1984; 11:1059–1065PubMedGoogle Scholar
  116. 116.
    Ben-Amitai D, Hodak E, David M: Cutaneous ulceration: an unusual sign of methotrexate toxicity — first report in a patient without psoriasis. Ann Pharmacother 1998; 32:651–653CrossRefPubMedGoogle Scholar
  117. 117.
    Kaplan DL, Olsen EA: Erosion of psoriatic plaques after chronic methotraxate administration. Int J Dermatol 1988; 27:59–62PubMedGoogle Scholar
  118. 118.
    Surville-Barland J, Caumes E, Ankri A, et al: Bleomycin-induced digital gangrene. Eur J Dermatol 1998; 8:221PubMedGoogle Scholar
  119. 119.
    Green JP: Steroid therapy and wound healing in surgical patients. Br J Surg 1965; 52:523–525PubMedGoogle Scholar
  120. 120.
    Anstead GM: Steroids, retinoids, and wound healing. Adv Wound Care 1998; 11:277–285PubMedGoogle Scholar
  121. 121.
    Pollack SV: Wound healing: A review. 4. Systemic medications affecting wound healing. J Dermatol Surg Oncol 1982; 8:667–672PubMedGoogle Scholar
  122. 122.
    Mogford JE, Mustoe TA: Experimental models of wound healing. In: Falanga V (ed) Cutaneous Wound Healing. London: Martin Dunitz. 2001; pp 109–122Google Scholar
  123. 123.
    Lenco W, McKnight M, MacDonald AS: Effects of cortisone acetate, methylprednisolone, and medroxyprogesterone on wound contracture and epithelization in rabbits. Ann Surg 1975; 181:67–73PubMedGoogle Scholar
  124. 124.
    Durant S, Duval D, Homo-Delarche F: Factors involved in the control of fibroblast proliferation by glucocorticoids: a review. Endocr Rev 1986; 7:254–269PubMedGoogle Scholar
  125. 125.
    Hashimoto I, Nakanishi H, Shono Y, et al: Angiostatic effects of corticosteroid on wound healing of the rabbit ear. J Med Invest 2002; 49:61–66PubMedGoogle Scholar
  126. 126.
    Chedid M, Hoyle JR, Csaky KG, et al: Glucocorticoids inhibit keratinocyte growth factor production in primary dermal fibroblasts. Endocrinology 1996;137:2232–2237CrossRefPubMedGoogle Scholar
  127. 127.
    Stadelmann WK, Digenis AG, Tobin GR: Impediments to wound healing. Am J Surg 1998; 176[Suppl 2A]:39S–47SCrossRefGoogle Scholar
  128. 128.
    Autio P, Oikarinen A, Melkko J, et al: Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect. Br J Dermatol 1994; 131:660–663PubMedGoogle Scholar
  129. 129.
    Edwards LC, Dunphy JE: Wound healing. 2. Injury and abnormal repair. N Engl J Med 1958; 259: 275–285PubMedGoogle Scholar
  130. 130.
    Sandberg N: Time relationship between administration of cortisone and wound healing in rats. Acta Chir Scand 1964; 127:446–455PubMedGoogle Scholar
  131. 131.
    Kulick MI, Smith S, Hadler K: Oral ibuprofen: evaluation of its effect on peritendinous and the breaking strength of a tenorrhaphy. J Hand Surg [Am] 1986; 11:110–120Google Scholar
  132. 132.
    Lee KH: Studies on the mechanism of action of salicylates. 3. Effect of vitamin A on the 'wound healing retardation action of aspirin. J Pharm Sci 1968;57:1238–1240PubMedGoogle Scholar
  133. 133.
    Falcone RE, Nappi JF: Chemotherapy and wound healing. Surg Clin North Am 1984; 64:779–794PubMedGoogle Scholar
  134. 134.
    Cohen SC, Gabelnick HL, Johnson RK, Goldin A: Effects of antineoplastic agents on wound healing in mice. Surgery 1975; 78:238–244PubMedGoogle Scholar
  135. 135.
    McGrath P: Reflections on nutritional issues associated with cancer therapy. Cancer Pract 2002; 10:94–101CrossRefPubMedGoogle Scholar
  136. 136.
    Capra S, Ferguson M, Ried K: Cancer: impact of nutrition intervention outcome — nutrition issues for patients. Nutrition 2001; 17:769–772CrossRefPubMedGoogle Scholar
  137. 137.
    Donaldson SS, Lenon RA: Alterations of nutritional status: impact of chemotherapy and radiation therapy. Cancer 1979; 43[Suppl]:2036–2052PubMedGoogle Scholar
  138. 138.
    Alster Y, Varssano D, Loewenstein A, Lazar M: Delay of corneal wound healing in patients treated with colchicine. Ophthalmology 1997; l04:118–119Google Scholar
  139. 139.
    Joseph HL, Anderson GL, Barker JH, et al: Inhibition of wound contraction with colchicine and D-penicillamine. J Surg Res 1996; 61:197–200CrossRefPubMedGoogle Scholar
  140. 140.
    Williams GH: Hypertensive vascular diseases. In: Fauci As, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL (eds) Harrison's Principles of Internal Medicine,14th edn. New York: McGraw-Hill. 1998; pp 1380–1394Google Scholar
  141. 141.
    Parfitt K (ed) Nifedipine. In: Martindale — The complete drug reference, 32nd edn. London: Pharmaceutical Press. 1999; pp 916–922Google Scholar
  142. 142.
    Lewis JG: Adverse reactions to calcium antagonists. Drugs 1983; 25:196–222PubMedGoogle Scholar
  143. 143.
    Pierard-Franchimont C, Letawe C, Fumal I, et al: Gravitational syndrome and tensile properties of skin in the elderly. Dermatology 1998; 197:317–320CrossRefPubMedGoogle Scholar
  144. 144.
    Casley-Smith JR, Casley-Smith JR: Pathology of oedema-Effect of oedema. In: Casley-Smith JR, Casley-Smith JR (eds) Modern Treatment for Lymphoedema, 5th revised edn. Adelaide: The Lymphoedema Association of Australia. 1997; pp 60–73Google Scholar
  145. 145.
    Luca S, Romeo S: Edema and skin ulcers of the lower limbs as a collateral effect of nifedipine. A clinical case report. Minerva Cardioangiol 1999; 47:219–222PubMedGoogle Scholar
  146. 146.
    Weir MR: Dihydropyridine calcium antagonists. In: Izzo JL, Black HR (eds) Hypertension Primer. The Essentials of High Blood Pressure, 2nd edn. Dallas: American Heart Association (Lippincott Williams & Wilkins). 1999; pp 379–381Google Scholar
  147. 147.
    Levine TB, Sica DA: Non-dihydropyridine calcium antagonists. In: Izzo JL, Black HR (eds) Hypertension Primer. The Essentials of High Blood Pressure. 2nd edn. Dallas: American Heart Association (Lippincott Williams & Wilkins). 1999; pp 382–384Google Scholar
  148. 148.
    Valencia IC, Kerdel FA: Topical glucocorticoides. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (eds) Fitzpatrick's Dermatology in General Medicine, 6th edn. New York: McGraw-Hill. 2003; pp 2324–2328Google Scholar
  149. 149.
    Lever WF, Schaumburg-Lever G: Eruptions due to drugs. In: Histopathology of the Skin, 7th edn. Philadelphia: J.B. Lippincott. 1990; pp 284–297Google Scholar
  150. 150.
    Rowell NR, Goodfield MJD: The ‘connective tissue diseases'. In: Champion RH, Burton JL, Burns DA, Breathnach SM (eds) Rook/Wilkinson/Ebling Text-book of Dermatology, 6th edn. Oxford: Blackwell Scientific Publications. 1998; pp 2437–2575Google Scholar
  151. 151.
    Tu JH, Eisen AZ: Scleroderma. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB (eds) Fitzpatrick's Dermatology in General Medicine, 5th edn. New York: McGraw-Hill. 1999; pp 2023–2033Google Scholar
  152. 152.
    Leshin B, Piette WW, Caplan RM: Morphea after bromocriptine therapy. Int J Dermatol 1989; 28:177–179PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Personalised recommendations